Genomic Determinants of Clinical Outcomes in Multiple Myeloma with t(11;14)(CCND1;IGH) Treated with Venetoclax
Kaddoura M, Wiedmeier-Nutor J, Gupta V, Ziccheddu B, Shivaram S, Tang H, Fonseca R, Durante M, Matulis S, Jelinek T, Landgren O, Mitsiades C, Bergsagel P, Braggio E, Boise L, Fonseca R, Kumar S, Maura F, Baughn L. Genomic Determinants of Clinical Outcomes in Multiple Myeloma with t(11;14)(CCND1;IGH) Treated with Venetoclax. Blood 2024, 144: 249. DOI: 10.1182/blood-2024-204071.Peer-Reviewed Original ResearchProgression free survivalSingle nucleotide variantsWhole-genome sequencingMultiple myelomaMM patientsFocal deletionsCopy number variantsMechanisms of resistanceTraining cohortValidation cohortChronic lymphocytic leukemia treated with venetoclaxDisease progressionMAPK pathwayMedian progression free survivalPopulation of MM patientsDeterminants of clinical outcomeAnti-CD38 agentsTreated with venetoclaxComprehensive genomic profilingMAPK pathway mutationsStructural variantsAcute myeloid leukemiaGenomic eventsLoss of NoxaNovel drug combinationsIberdomide Alone or in Combination with Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma (SMM)
Joseph N, Kaufman J, Hofmeister C, Gupta V, Burton B, Pruitt R, Nooka A, Dhodapkar M, Lonial S. Iberdomide Alone or in Combination with Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma (SMM). Blood 2024, 144: 1983-1983. DOI: 10.1182/blood-2024-210335.Peer-Reviewed Original ResearchSafety run-inProgression free survivalHigh-risk smoldering myelomaSmoldering multiple myelomaSmoldering myelomaMultiple myelomaRun-inHigh-risk smoldering multiple myelomaRisk of progression to myelomaNo dose limiting toxicitiesRate of tumor regressionProgression to myelomaRecurrent grade 3Treatment of intermediate-Grade 3 thrombocytopeniaCycles of therapyDose-limiting toxicityMedian patient ageOverall survival benefitStem cell collectionToxic therapeutic optionsRisk stratification modelTreatment of intermediateRelapsed myelomaCryptococcal meningitisCharacterization of Newly Diagnosed Multiple Myeloma (NDMM) Patients with Early Progression Following Induction with Daratumumab, Lenalidomide, Bortezomib and Dexamethasone (D-RVd)
Gu L, Joseph N, Gupta V, Hofmeister C, Dhodapkar M, Lonial S, Nooka A, Kaufman J. Characterization of Newly Diagnosed Multiple Myeloma (NDMM) Patients with Early Progression Following Induction with Daratumumab, Lenalidomide, Bortezomib and Dexamethasone (D-RVd). Blood 2024, 144: 3780. DOI: 10.1182/blood-2024-211474.Peer-Reviewed Original ResearchNewly diagnosed myelomaProgression free survivalInternational Myeloma Working GroupD-RVdEarly progressionData cutoffMedian followMedian time to progressionYear progression free survivalNewly diagnosed multiple myelomaHigh riskEstimate 3-year survivalPresence of del(17pR-ISS-3Time to progressionEffective induction regimenFirst-line therapyStem cell transplantationDepth of responseDocumented disease progressionCohort of patientsAge of diagnosisLong-term outcomesAlternative treatment approachesMedian OS